Roche
Roche's Pharma Day Targets Fail to Win Over Investors
The Swiss drugmaker unveiled ambitious R&D goals and cost-cutting plans, but shares slipped as investors remained unimpressed with the outlook.
Roche pushes aggressive pipeline expansion at Pharma Day, cites AI and new "Bar" criteria
Roche outlined a goal of up to 20 new drugs by 2030, introduced a stricter "Bar" framework for candidate selection and highlighted artificial‑intelligence integration across research, aiming for >30 bn CHF sales from top prospects.
Swiss Market Holds Steady Amid Mixed US Openings; UBS Regulatory Loss Weighs on Blue Chips
The Swiss Market Index (SMI) held near break-even, while UBS faced losses after a Ständerat ruling on stricter capital requirements. US markets opened mixed, with Nasdaq futures unchanged but Dow Jones and S&P 500 futures rising slightly.
Swiss Market Index holds gains as UBS leads SMI; 8 of 20 SMI stocks advance
The Swiss SMI closed slightly above 14,000 points after UBS led gains, while regulatory uncertainty over its capital requirements weighed on the index.
SMI Gains 0.7%, Defensive Stocks Offset AI Selloff as Oil Pushes Above $107
The Swiss benchmark index recovered part of last week's losses thanks to Roche, Novartis and Nestlé, while AI-linked tech names and building-material stocks fell on rising energy costs and Fed rate-hike expectations.
EU Approves Roche’s Susvimo for Neovascular AMD Treatment
The European Commission has granted marketing authorization for Roche’s implant-based Susvimo, marking the first continuous-delivery option for neovascular age-related macular degeneration.
Swiss Economic Calendar: SNB Policy Update, Federal Votes, Roche Pharma Day This Week
The Swiss National Bank will release its balance of payments and monetary policy assessment this week, alongside federal votes on Sep 27 and earnings from firms including Hilti, Hilti and Roche.
Swiss Stocks rebound early week; Roche, Novartis lead, ABB and tech drag
The SMI rose 0.6% to 13,854 in a first countermove after last week's >4% slide. Pharmaceutical giants led gains while AI-linked and construction-materials names faced pressure from rising Brent crude above $107.
Swiss and US markets rise on Fed independence, Logitech leads SMI
Swiss indices closed higher on Thursday, with Logitech leading gains, while US markets benefited from falling oil prices and the Fed’s commitment to inflation control.
US stocks open higher; SMI extends gains as Fed decision calms markets
Wall Street leads gainers after the Fed raised rates 25 basis points. The SMI climbs, tech stocks surge pre-market, and UBS capital-rule debate is deferred.
US Futures Rise as SMI Falls; Nestlé Dips on Russia Asset Seizure
S&P 500 and Nasdaq futures advance ahead of US open, while Switzerland's SMI drops 0.2% — Nestlé falls over temporary Russian control loss and Swisscom is set for index replacement.
SMI rises 0.2% as Fed delivers; UBS gains, Rieter plunges after downgrade
The Swiss market extends its early-week gains following the Fed's expected 25-bp hike. Helvetia Baloise surges on strong H1 results while Rieter drops after a UBS downgrade to Sell.
SMI Edges Higher on Fed Relief; UBS Decision Delayed, Rieter Slumps on Downgrade
Swiss benchmark gains 0.2% as investors welcome Fed's resolute inflation stance; UBS advances ahead of capital-rule vote while Rieter plunges after downgrade to Sell.
Swiss Market Index holds gains amid Fed hike, UBS gains amid Ständerat vote
The SMI advances modestly as the Swiss market reacts to the Fed’s 25 bps rate hike and UBS’ capital rules vote, while Roche and Rieter face profit-taking pressures.
Swiss Market Index rises as UBS gains amid Fed rate hike, Helvetia Baloise outperforms
UBS gains after Ständerat approves stricter capital rules; Roche and Rieter face downgrades; oil prices ease amid Saudi export diversification efforts.
Swiss Market Index rises; Roche downgraded, Rieter hit by UBS rating cut
Swiss equities mixed as SMI gains, but Roche and Rieter face downgrades; oil prices dip amid geopolitical uncertainty and Fed rate hike expectations.
Novartis Plunges After Failed Muscle-Disease Trial; SMI Slides 1.3%
Novartis tumbled nearly 10% after its del-desiran candidate missed a Phase III primary endpoint, erasing roughly CHF 24 billion in market value and pulling the SMI lower. Nestlé and Roche helped stem the damage.
Mirabaud sees Swiss equities as global niche leaders, not just defensive
Daniele Scilingo sees Swiss stocks as global niche leaders, warns AI valuations are stretched, and points to compounders, China adaptation, pharma innovation and UBS.
Swiss SMI slides over 1% as Novartis tumbles on failed drug trial
SMI fell 1.2% to 14,221 points, led by a 4.2% drop in Novartis after its Pelacarsen trial missed; other health‑care stocks and Schindler also fell, while Kühne+Nagel and ABB posted modest gains.
Swiss equities slip as Roche, Novartis drag; ABB gains, yen hits 7‑month high
The SMI fell about 1% to 14,221 points, led by 3%‑plus losses in Novartis and Roche after a failed Pelacarsen trial. ABB rose, while the yen strengthened to 154.07 per dollar, its lowest level in seven months.
Swiss SMI edges up 0.2% as Logitech and Roche lead gains, Richemont and Nestlé fall
The Swiss Market Index closed at 14,394 points, up 0.22%, driven by Logitech (+3.3%) and Roche (+2.1%). Luxury stocks lagged, while US software shares surged on Snowflake’s outlook.
Swiss stocks rise as Roche leads; Richemont falls on luxury sector weakness
Swiss Market Index edges up 0.12% as Roche gains on licensing deal, while Richemont drops 2.4% amid broader luxury sector decline. Swiss franc strengthens to 0.9384 per euro after August inflation surprise.
US stocks rise on Fed rate pause hopes; Swiss franc strengthens
Wall Street advances as investors bet on a September Fed pause, while the Swiss franc gains after higher-than-expected Swiss inflation. SMI mixed as Nestlé weighs on index.
Swiss stocks rise on US gains; Nestlé, Richemont drag; franc strengthens
Swiss Market Index edges up 0.2% after early 0.5% gain as Nestlé drags; Roche and Logitech lead gains. Euro falls to 0.9384 francs as Swiss inflation surprises.